This CPB has been revised for ziv-aflibercept (Zaltrap) to remove ‘appendiceal adenocarcinoma, or anal adenocarcinoma’ from the criteria for initial approval to align with NCCN. This CPB has been updated with  the following: (i) added additional Dosage and Administration information, and (ii) added and reorganized subheaders.